Premium
Resolution of paraneoplastic immune thrombocytopenia following everolimus treatment for metastatic renal cell carcinoma
Author(s) -
Zheng S.,
Chan H.,
Epstein R. J.,
Joseph J. E.
Publication year - 2015
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.12779
Subject(s) - medicine , everolimus , renal cell carcinoma , malignancy , refractory (planetary science) , immune system , immunotherapy , carcinoma , oncology , immunology , physics , astrobiology
Autoimmune thrombocytopenia is an uncommon but reported paraneoplastic manifestation of renal cell carcinoma ( RCC ). Treatment usually involves management of the underlying malignancy; however, steroids have shown a benefit in published case reports. Here, we describe a patient with profound thrombocytopenia secondary to metastatic RCC . It was refractory to steroid and intravenous immunoglobulin, but the platelet count improved markedly following initiation of everolimus. The possible explanation includes immunomodulation, tumour lysis or a combination of both effects. This is the first reported case of everolimus used in paraneoplastic thrombocytopenia from RCC . More studies are needed for further investigation of its potential use in secondary immune thrombocytopenia from RCC and perhaps other malignancies.